CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 103 enrolled
Drug / intervention
Standard of Care for Haemophilia Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04165135
NCT04165135N/ACompleted

A Multicenter, Non-Interventional Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Patients With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment

Hoffmann-La Roche·observational·Posted Nov 15, 2019·Updated Jul 12, 2024

In Brief

An observational study evaluating Standard of Care for Haemophilia A for Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor and 2 related conditions. Completed, enrolled 103 participants across 17 sites.

Detailed Summary

This multicenter, non-interventional, prospective study will collect information about activity status, bleeds, health-related quality of life (HRQoL), health status, and safety in participants with moderate or severe haemophilia A without factor VIII (FVIII) inhibitors, who are being treated in accordance with normal clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 15, 2019
Enrollment StartFeb 24, 2020
Primary CompletionApr 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.6 years ago

Interventions

Standard of Care for Haemophilia Adrug

There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.